Ranbaxy Receives Tentative Approval to Market Tolterodine Tartrate Tablets
16th Sep 2005, 17:35 GMT
Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Labs, announced that RLL has received tentative approval from the US FDA to manufacture and market Tolterodine Tartrate Tablets, 1 mg and 2 mg.
Latest news from FDA News News from myHealthcareNews.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting